Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and north-osaka multicenter Direct Oral AntiCoagulant (SET DOAC) Registry
How to cite: Suwa, M.; Mori, I.; Kino, M.; Matsui, Y.; Yoshinaga, M.; Takahashi, H.; Takagi, M.; Yoshida, A.; Ichikawa, M.; Nakajima, O.; Tanimura, M.; Shimoyama, H.; Saitoh, H.; Sasaki, I.; Suzuki, T.; Uemae, S. Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and north-osaka multicenter Direct Oral AntiCoagulant (SET DOAC) Registry. Preprints 2024, 2024071032. https://doi.org/10.20944/preprints202407.1032.v1 Suwa, M.; Mori, I.; Kino, M.; Matsui, Y.; Yoshinaga, M.; Takahashi, H.; Takagi, M.; Yoshida, A.; Ichikawa, M.; Nakajima, O.; Tanimura, M.; Shimoyama, H.; Saitoh, H.; Sasaki, I.; Suzuki, T.; Uemae, S. Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and north-osaka multicenter Direct Oral AntiCoagulant (SET DOAC) Registry. Preprints 2024, 2024071032. https://doi.org/10.20944/preprints202407.1032.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)